ATE401877T1 - Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen - Google Patents

Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen

Info

Publication number
ATE401877T1
ATE401877T1 AT05716814T AT05716814T ATE401877T1 AT E401877 T1 ATE401877 T1 AT E401877T1 AT 05716814 T AT05716814 T AT 05716814T AT 05716814 T AT05716814 T AT 05716814T AT E401877 T1 ATE401877 T1 AT E401877T1
Authority
AT
Austria
Prior art keywords
derivatives
methylenamide
cardiovascular diseases
prevention
formula
Prior art date
Application number
AT05716814T
Other languages
English (en)
Inventor
Van Huijsduijnen Rob Hooft
Vincent Richard
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of ATE401877T1 publication Critical patent/ATE401877T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05716814T 2004-02-27 2005-02-25 Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen ATE401877T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04100778 2004-02-27

Publications (1)

Publication Number Publication Date
ATE401877T1 true ATE401877T1 (de) 2008-08-15

Family

ID=34896106

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05716814T ATE401877T1 (de) 2004-02-27 2005-02-25 Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen

Country Status (23)

Country Link
US (1) US20070185118A1 (de)
EP (1) EP1732534B1 (de)
JP (1) JP5001138B2 (de)
KR (1) KR101188940B1 (de)
CN (1) CN1933827B (de)
AT (1) ATE401877T1 (de)
AU (1) AU2005216649B2 (de)
BR (1) BRPI0508080A (de)
CA (1) CA2554919C (de)
CY (1) CY1108252T1 (de)
DE (1) DE602005008412D1 (de)
DK (1) DK1732534T3 (de)
EA (1) EA011811B1 (de)
ES (1) ES2308458T3 (de)
HR (1) HRP20080367T3 (de)
IL (1) IL177494A (de)
NO (1) NO20064295L (de)
PL (1) PL1732534T3 (de)
PT (1) PT1732534E (de)
RS (1) RS50596B (de)
SI (1) SI1732534T1 (de)
UA (1) UA84453C2 (de)
WO (1) WO2005082347A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040612A2 (en) * 2002-01-29 2005-04-30 Applied Research Systems Ars Holding N.V. Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps)
WO2005012280A1 (en) 2003-07-21 2005-02-10 Applied Research Systems Ars Holding N.V. Alkynyl aryl carboxamides
US7884234B2 (en) 2006-10-12 2011-02-08 Institute Of Medicinal Molecular Design, Inc. N-phenyloxamide derivatives
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
US9045685B2 (en) 2011-08-29 2015-06-02 Ticona Llc Cast molded parts formed from a liquid crystalline polymer
WO2013032976A1 (en) 2011-08-29 2013-03-07 Ticona Llc High flow liquid crystalline polymer composition
JP2014529627A (ja) 2011-08-29 2014-11-13 ティコナ・エルエルシー 芳香族アミド化合物
US9057016B2 (en) 2011-08-29 2015-06-16 Ticona Llc Melt polymerization of low melt viscosity liquid crystalline polymers
US8852730B2 (en) 2011-08-29 2014-10-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
US8669341B2 (en) 2011-08-29 2014-03-11 Ticona Llc Solid-state polymerization of a liquid crystalline polymer
US8906258B2 (en) 2011-08-29 2014-12-09 Ticona Llc Heat-resistant liquid crystalline polymer composition having a low melting temperature
CN103764793B (zh) 2011-08-29 2016-09-14 提克纳有限责任公司 高流动液晶聚合物组合物
US9074133B2 (en) 2011-08-29 2015-07-07 Ticona Llc Thermotropic liquid crystalline polymer with improved low shear viscosity
US20150337212A1 (en) 2012-12-17 2015-11-26 Shell Oil Company Integrated gas-to-liquids condensate process
WO2014130275A2 (en) 2013-02-22 2014-08-28 Ticona Llc High performance polymer composition with improved flow properties
CN113912988A (zh) 2013-06-07 2022-01-11 提克纳有限责任公司 高强度热致液晶聚合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60028791T2 (de) * 1999-09-10 2007-05-24 Novo Nordisk A/S Modulatoren der protein tyrosin phosphatase (ptpases)
US6627767B2 (en) * 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
DE10117823A1 (de) * 2001-04-10 2002-10-17 Merck Patent Gmbh Oxalsäurederivate
US20030055058A1 (en) * 2001-06-07 2003-03-20 Wyeth Combination of a PTPase inhibitor and an ACE inhibitor
WO2002098408A1 (en) * 2001-06-07 2002-12-12 Wyeth Ptpase inhibitors for improving cardiovascular risk profile
HRP20040612A2 (en) * 2002-01-29 2005-04-30 Applied Research Systems Ars Holding N.V. Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps)

Also Published As

Publication number Publication date
AU2005216649A1 (en) 2005-09-09
KR101188940B1 (ko) 2012-10-08
DE602005008412D1 (de) 2008-09-04
RS50596B (sr) 2010-05-07
HK1098073A1 (en) 2007-07-13
IL177494A0 (en) 2006-12-31
CA2554919A1 (en) 2005-09-09
EA200601511A1 (ru) 2007-02-27
CN1933827A (zh) 2007-03-21
DK1732534T3 (da) 2008-11-17
JP5001138B2 (ja) 2012-08-15
ES2308458T3 (es) 2008-12-01
AU2005216649B2 (en) 2010-09-09
IL177494A (en) 2011-06-30
EP1732534A1 (de) 2006-12-20
JP2007524701A (ja) 2007-08-30
WO2005082347A1 (en) 2005-09-09
UA84453C2 (ru) 2008-10-27
KR20060129066A (ko) 2006-12-14
SI1732534T1 (sl) 2008-10-31
BRPI0508080A (pt) 2007-07-17
PL1732534T3 (pl) 2008-12-31
PT1732534E (pt) 2008-08-08
CA2554919C (en) 2013-04-16
CN1933827B (zh) 2011-07-27
US20070185118A1 (en) 2007-08-09
CY1108252T1 (el) 2014-02-12
NO20064295L (no) 2006-09-22
EA011811B1 (ru) 2009-06-30
HRP20080367T3 (en) 2008-09-30
EP1732534B1 (de) 2008-07-23

Similar Documents

Publication Publication Date Title
CY1108252T1 (el) Χρηση παραγωγων μεθυλενο αμιδης στις καρδιαγγειακες διαταραχες
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE602005009318D1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
DE602007009095D1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
ATE517896T1 (de) P38-kinase-inhibitoren
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
NO20071343L (no) Substituerte fenylaminotiazoler og anvendelse derav
DE602004022668D1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
NO20071574L (no) Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander.
ATE331709T1 (de) Substituierte 3-carbonyl-1-yl essigsäure derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
DE602005010821D1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE432260T1 (de) Pyridinderivate als pkc-theta-hemmer
ATE411984T1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
ATE407119T1 (de) Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
MX2008009161A (es) Tratamiento de enfermedad cardiovascular en mexicano-americanos, usando nebivolol.
EP1812007A4 (de) Pyridazinverbindungen und verfahren
DE602005008099D1 (de) Pyrrolopyridin-2-karbonsäureamid-derivat zur verwendung als inhibitor gegen glykogenphosphorylase
BR0315092A (pt) Derivados de piperidina como inibidores de ccr5
MEP25308A (en) Aminoindazole derivatives and use thereof as kinase inhibitors
EA200602083A1 (ru) Новые пиперазиновые производные диалкилоксиндолов
DE602004010186D1 (de) Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1732534

Country of ref document: EP

EEFA Change of the company name